These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 21830902)

  • 1. Baculovirus-produced influenza virus-like particles in mammalian cells protect mice from lethal influenza challenge.
    Tang XC; Lu HR; Ross TM
    Viral Immunol; 2011 Aug; 24(4):311-9. PubMed ID: 21830902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
    Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Production and characterization of mammalian virus-like particles from modified vaccinia virus Ankara vectors expressing influenza H5N1 hemagglutinin and neuraminidase.
    Schmeisser F; Adamo JE; Blumberg B; Friedman R; Muller J; Soto J; Weir JP
    Vaccine; 2012 May; 30(23):3413-22. PubMed ID: 22465746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
    Smith GE; Flyer DC; Raghunandan R; Liu Y; Wei Z; Wu Y; Kpamegan E; Courbron D; Fries LF; Glenn GM
    Vaccine; 2013 Sep; 31(40):4305-13. PubMed ID: 23891795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemagglutinin displayed baculovirus protects against highly pathogenic influenza.
    Tang XC; Lu HR; Ross TM
    Vaccine; 2010 Oct; 28(42):6821-31. PubMed ID: 20727393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.
    Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC
    Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.
    Mahmood K; Bright RA; Mytle N; Carter DM; Crevar CJ; Achenbach JE; Heaton PM; Tumpey TM; Ross TM
    Vaccine; 2008 Oct; 26(42):5393-9. PubMed ID: 18706956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fabrication of influenza virus-like particles using M2 fusion proteins for imaging single viruses and designing vaccines.
    Wei HJ; Chang W; Lin SC; Liu WC; Chang DK; Chong P; Wu SC
    Vaccine; 2011 Sep; 29(41):7163-72. PubMed ID: 21651946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice.
    Pushko P; Tumpey TM; Bu F; Knell J; Robinson R; Smith G
    Vaccine; 2005 Dec; 23(50):5751-9. PubMed ID: 16143432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporation of conserved nucleoprotein into influenza virus-like particles could provoke a broad protective immune response in BALB/c mice and chickens.
    Xue C; Tian G; Chen X; Liu Q; Ma J; Xu S; Li X; Chen H; Cao Y
    Virus Res; 2015 Jan; 195():35-42. PubMed ID: 25312452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain.
    de Wit E; Munster VJ; Spronken MI; Bestebroer TM; Baas C; Beyer WE; Rimmelzwaan GF; Osterhaus AD; Fouchier RA
    J Virol; 2005 Oct; 79(19):12401-7. PubMed ID: 16160167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine.
    Crevar CJ; Ross TM
    Virol J; 2008 Oct; 5():131. PubMed ID: 18957098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system.
    Brett IC; Johansson BE
    Virology; 2005 Sep; 339(2):273-80. PubMed ID: 15996702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge.
    Galarza JM; Latham T; Cupo A
    Viral Immunol; 2005; 18(1):244-51. PubMed ID: 15802970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baculovirus as an avian influenza vaccine vector: differential immune responses elicited by different vector forms.
    Chen CY; Liu HJ; Tsai CP; Chung CY; Shih YS; Chang PC; Chiu YT; Hu YC
    Vaccine; 2010 Nov; 28(48):7644-51. PubMed ID: 20883735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reverse micelle-encapsulated recombinant baculovirus as an oral vaccine against H5N1 infection in mice.
    Prabakaran M; Madhan S; Prabhu N; Geng GY; New R; Kwang J
    Antiviral Res; 2010 May; 86(2):180-7. PubMed ID: 20153776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice.
    D'Aoust MA; Lavoie PO; Couture MM; Trépanier S; Guay JM; Dargis M; Mongrand S; Landry N; Ward BJ; Vézina LP
    Plant Biotechnol J; 2008 Dec; 6(9):930-40. PubMed ID: 19076615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge.
    Haynes JR; Dokken L; Wiley JA; Cawthon AG; Bigger J; Harmsen AG; Richardson C
    Vaccine; 2009 Jan; 27(4):530-41. PubMed ID: 19026705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective immunity elicited by a pseudotyped baculovirus-mediated bivalent H5N1 influenza vaccine.
    Wu Q; Xiao S; Fan H; Li Y; Xu J; Li Z; Lu W; Su X; Zou W; Jin M; Chen H; Fang L
    Antiviral Res; 2011 Dec; 92(3):493-6. PubMed ID: 22020305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.